ClinicalTrials.gg
TerminatedNCT03968419CANOPY-NUpdated Jun 20, 2024Results posted

This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC.

A Phase 2 interventional study of Canakinumab and Pembrolizumab in Non-small Cell Lung Cancer, sponsored by Novartis Pharmaceuticals. Terminated at 29 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-20.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Why this study was terminated
Study early terminated due to low enrollment compared to the anticipated figures.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
88
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 127 studies testing pembrolizumab in Carcinoma, Non-Small-Cell Lung — 29 open to participants now, 48 under way, 13 of them phase 3. pembrolizumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
58th of 127
88 · median 65
Started
2019
with 7 others
Phase 2
65 of 127
20 open now
Registered
64th of 127
by date

Among the 127 studies testing pembrolizumab in Carcinoma, Non-Small-Cell Lung, this one is the 58th largest by enrollment, is one of 8 that started in 2019, is one of 65 in phase 2, and was the 64th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

29 of the 127 studies testing pembrolizumab in Carcinoma, Non-Small-Cell Lung are open now, in 10 countries. Recruiting first, the newest first:

24 more — sign in →

By country, each count listing its studies:

All 29 open studies →

About pembrolizumab

pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies testing pembrolizumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The purpose of this study was to evaluate the major pathological response (MPR) rate of canakinumab given as a neoadjuvant treatment, either as single agent or in combination with pembrolizumab, in addition to evaluate the MPR of pembrolizumab as a single agent and the dynamic of the tumor microenvironment changes on treatment.

Read the detailed description

This was a randomized, phase II, open-label study evaluating canakinumab, an anti-IL-1β monoclonal antibody, or pembrolizumab, a monoclonal antibody designed to block the PD-1 receptor, as monotherapy or in combination as neoadjuvant therapy. The study population included adult subjects with resectable non-small cell lung cancer (NSCLC) planned for surgery in approximately 4-6 weeks. Subjects were treated for a maximum duration of 6 weeks (2 cycles) until surgery, progression, unacceptable toxicity or discontinuation from the study treatment for any other reason.

Subjects were randomized in a 2:2:1 ratio to one of the 3 treatment arms (canakinumab alone or canakinumab in combination with pembrolizumab or pembrolizumab alone). Surgery was performed between 4 to 6 weeks after the first dose of study treatment.

All randomized subjects were followed for safety for up to 130 days following the last dose of study treatment (safety follow-up period).

03

Conditions studied

  • Non-small Cell Lung Cancer

Keywords

  • ACZ885
  • canakinumab
  • pembrolizumab
  • NSCLC
  • non-small cell lung cancer
  • non small cell lung cancer
  • early stage NSCLC
  • squamous
  • non-squamous,
  • MPR
  • major pathological response
  • hs-CRP
  • PD-L1
  • hsCRP
  • surgery
  • neo-adjuvant
  • neo adjuvant
  • CD8
  • hs-IL-6
  • CANOPY
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key inclusion criteria:

  • confirmed NSCLC stage IB-IIIA (per AJCC 8th edition), deemed suitable for primary resection by treating surgeon, except for N2 and T4 tumors.
  • Subject must have been eligible for surgery and with a planned surgical resection in approximately 4-6 weeks (after the first dose of study treatment).
  • A mandatory newly obtained tissue from primary site was required for study enrollment. An archival biopsy was also acceptable if obtained up to 5 months before first day of study treatment and if the subject did not go through antineoplastic systemic therapies between biopsy collection date and beginning of study treatment.
  • (ECOG) performance status of 0 or 1.

Key exclusion criteria:

  • Subjects with unresectable or disease.
  • History of severe reactions to monoclonal antibodies, which in the opinion of the investigator may pose an increased risk of serious infusion reaction
  • Subjects who received prior systemic therapy (including chemotherapy, other anti-cancer therapies and any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways) in the past 3 years before screening
  • Active disease that has required systemic treatment in the past 2 years prior to randomization. Control of the disorder with replacement therapy was permitted
  • Subject with suspected or proven state or infections
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
88 participants (actual)

Study arms

  • Experimental
    Canakinumab monotherapy

    Participants received 200 mg of canakinumab once every 3 weeks for a maximum duration of 6 weeks prior to surgery

    Drug: Canakinumab

  • Experimental
    Canakinumab + pembrolizumab

    Participants received 200 mg of canakinumab in combination with 200 mg of pembrolizumab once every 3 weeks for a maximum duration of 6 weeks prior to surgery

    Drug: Canakinumab · Drug: Pembrolizumab

  • Experimental
    Pembrolizumab monotherapy

    Participants received 200 mg of pembrolizumab every 3 weeks for a maximum duration of 6 weeks prior to surgery

    Drug: Pembrolizumab

Interventions

  • 200 mg of canakinumab administered via subcutaneous injections once every 3 weeks for a maximum duration of 6 weeks

    Also known as: ACZ885

  • 200 mg of pembrolizumab administered via infusion once every 3 weeks for a maximum duration of 6 weeks

06

What researchers measure

Primary outcomes

  1. Major Pathological Response (MPR) Rate at the Time of Surgery in Subjects Randomized to Canakinumab Monotherapy and in Combination With Pembrolizumab Based on Central Review

    MPR was defined as the percentage of participants with major pathological response (defined as ≤10% residual viable tumor cells on surgical samples). Any participant who had \>10% residual viable cancer cells, or started new antineoplastic therapy prior to surgery, or did not have the surgery performed, or had the surgery performed but with unevaluable MPR result, was considered as a non-responder. MPR was assessed at the time of surgery in all subjects randomized to canakinumab monotherapy and in combination with pembrolizumab based on central review.

    Time frame: At time of surgery (up to 6 weeks after first dose of study treatment)

Secondary outcomes

  1. Canakinumab Antidrug Antibodies (ADA) Prevalence

    Canakinumab ADA prevalence at baseline was calculated as the percentage of participants who had a canakinumab ADA positive result at baseline

    Time frame: Predose (0 hour) on Day 1 of Cycle 1 (Cycle=21 days)

  2. Canakinumab ADA Incidence

    Canakinumab ADA incidence on treatment was calculated as the percentage of participants who were canakinumab treatment-induced ADA positive (post-baseline ADA positive with ADA-negative sample at baseline) and canakinumab treatment-boosted ADA positive (post-baseline ADA positive with titer that is at least the fold titer change greater than the ADA-positive baseline titer)

    Time frame: From baseline (Predose on Day 1 of Cycle 1) up to 130 days after last dose of study treatment (assessed up to 24.6 weeks). Cycle = 21 days

  3. Pembrolizumab ADA Prevalence

    Pembrolizumab ADA prevalence at baseline was calculated as the percentage of participants who had a pembrolizumab ADA positive result at baseline

    Time frame: Predose (0 hour) on Day 1 of Cycle 1 (Cycle = 21 days)

  4. Pembrolizumab ADA Incidence

    Pembrolizumab ADA incidence on treatment was calculated as the percentage of participants who were pembrolizumab treatment-induced ADA positive (post-baseline ADA positive with ADA-negative sample at baseline) and pembrolizumab treatment-boosted ADA positive (post-baseline ADA positive with titer that is at least the fold titer change greater than the ADA-positive baseline titer)

    Time frame: From baseline (Predose on Day 1 of Cycle 1) up to 26 days after last dose of study treatment (assessed up to 10.7 weeks). Cycle = 21 days

  5. Overall Response Rate (ORR) Based on Local Investigator Assessment Using RECIST v1.1

    ORR is defined as the percentage of subjects with confirmed best overall response of complete response (CR) or partial response (PR), as per local investigator's assessment by RECIST 1.1. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters

    Time frame: From date of randomization to date of surgery, assessed up to 6 weeks

  6. Serum Canakinumab Concentration

    Canakinumab serum concentrations were determined at the specified time points.

    Time frame: Predose (0 hour) on Day 1 of Cycles 1 and 2 (Cycle =21 days)

  7. Serum Pembrolizumab Concentration

    Pembrolizumab serum concentrations were determined at the specified time points.

    Time frame: Predose (0 hour) and 0.5 hours post dose on Day 1 of Cycle 1 and predose on Cycle 2 (Cycle =21 days)

  8. Surgical Feasibility Rate

    Surgical feasibility rate was defined as the percentage of subjects who underwent surgery following study treatment.

    Time frame: Up to 6 weeks after first dose

  9. Major Pathological Response (MPR) Rate at the Time of Surgery in Subjects Randomized to Pembrolizumab Monotherapy Based on Central Review

    MPR was defined as the percentage of participants with major pathological response (defined as ≤10% residual viable tumor cells on surgical samples). Any participant who had \>10% residual viable cancer cells, or started new antineoplastic therapy prior to surgery, or did not have the surgery performed, or had the surgery performed but with unevaluable MPR result, was considered as a non-responder. MPR was assessed at the time of surgery in all subjects randomized to pembrolizumab monotherapy arm based on central review.

    Time frame: At time of surgery (up to 6 weeks after first dose)

  10. Difference in Major Pathological Response (MPR) Rate Between the Canakinumab Plus Pembrolizumab Arm and the Pembrolizumab Arm Based on Central Review

    MPR was defined as the percentage of participants with ≤10% residual viable tumor cells on surgical samples. MPR was assessed at the time of surgery based on central review. The difference in MPR rate between the canakinumab plus pembrolizumab arm and the pembrolizumab arm based on central review along with the Chang and Zhang confidence interval was assessed.

    Time frame: At time of surgery (up to 6 weeks after first dose of study treatment)

  11. Major Pathological Response (MPR) Rate at the Time of Surgery in All Subjects Based on Local Review

    MPR was defined as the percentage of participants with major pathological response (defined as ≤10% residual viable tumor cells on surgical samples). Any participant who had \>10% residual viable cancer cells, or started new antineoplastic therapy prior to surgery, or did not have the surgery performed, or had the surgery performed but with unevaluable MPR result, was considered as a non-responder. MPR was assessed at the time of surgery in all subjects based on local review.

    Time frame: At time of surgery (up to 6 weeks after first dose)

  12. Major Pathological Response (MPR) Rate Based on the Levels of Biomarkers

    MPR was defined as the percentage of participants with major pathological response (defined as ≤10% residual viable tumor cells on surgical samples). Any participant who had \>10% residual viable cancer cells, or started new antineoplastic therapy prior to surgery, or did not have the surgery performed, or had the surgery performed but with unevaluable MPR result, was considered as a non-responder. MPR rate was analyzed by the biomarker subgroups at baseline. Biomarkers included PD-L1, CD8, hs-CRP and hs-IL-6.

    Time frame: From date of randomization up to 6 weeks after first dose

07

Results

Posted Jul 3, 2023

Participant flow

The study was conducted in 29 centers across 12 countries.

Treatment Period
Participant flow — Treatment Period
MilestoneCanakinumab MonotherapyCanakinumab + PembrolizumabPembrolizumab Monotherapy
Started353518
Completed353517
Not completed001
Withdrew: Adverse event001
Safety Follow-up Period
Participant flow — Safety Follow-up Period
MilestoneCanakinumab MonotherapyCanakinumab + PembrolizumabPembrolizumab Monotherapy
Started353518
Completed303217
Not completed531
Withdrew: Death321
Withdrew: Subject decision210

Outcome measures

PrimaryMajor Pathological Response (MPR) Rate at the Time of Surgery in Subjects Randomized to Canakinumab Monotherapy and in Combination With Pembrolizumab Based on Central Review

MPR was defined as the percentage of participants with major pathological response (defined as ≤10% residual viable tumor cells on surgical samples). Any participant who had \>10% residual viable cancer cells, or started new antineoplastic therapy prior to surgery, or did not have the surgery performed, or had the surgery performed but with unevaluable MPR result, was considered as a non-responder. MPR was assessed at the time of surgery in all subjects randomized to canakinumab monotherapy and in combination with pembrolizumab based on central review.

Time frame:
At time of surgery (up to 6 weeks after first dose of study treatment)
Reported as:
Number · Percentage of participants
Major Pathological Response (MPR) Rate at the Time of Surgery in Subjects Randomized to Canakinumab Monotherapy and in Combination With Pembrolizumab Based on Central Review
Percentage of participantsCanakinumab MonotherapyCanakinumab + Pembrolizumab
Major Pathological Response (MPR) Rate at the Time of Surgery in Subjects Randomized to Canakinumab Monotherapy and in Combination With Pembrolizumab Based on Central Review2.9 (0.07 to 14.92)17.1 (6.56 to 33.65)
SecondaryCanakinumab Antidrug Antibodies (ADA) Prevalence

Canakinumab ADA prevalence at baseline was calculated as the percentage of participants who had a canakinumab ADA positive result at baseline

Time frame:
Predose (0 hour) on Day 1 of Cycle 1 (Cycle=21 days)
Reported as:
Count of participants · Participants
Canakinumab Antidrug Antibodies (ADA) Prevalence
ParticipantsCanakinumab MonotherapyCanakinumab + Pembrolizumab
Canakinumab Antidrug Antibodies (ADA) Prevalence00
SecondaryCanakinumab ADA Incidence

Canakinumab ADA incidence on treatment was calculated as the percentage of participants who were canakinumab treatment-induced ADA positive (post-baseline ADA positive with ADA-negative sample at baseline) and canakinumab treatment-boosted ADA positive (post-baseline ADA positive with titer that is at least the fold titer change greater than the ADA-positive baseline titer)

Time frame:
From baseline (Predose on Day 1 of Cycle 1) up to 130 days after last dose of study treatment (assessed up to 24.6 weeks). Cycle = 21 days
Reported as:
Count of participants · Participants
Canakinumab ADA Incidence
ParticipantsCanakinumab MonotherapyCanakinumab + Pembrolizumab
Canakinumab ADA Incidence10
SecondaryPembrolizumab ADA Prevalence

Pembrolizumab ADA prevalence at baseline was calculated as the percentage of participants who had a pembrolizumab ADA positive result at baseline

Time frame:
Predose (0 hour) on Day 1 of Cycle 1 (Cycle = 21 days)
Reported as:
Count of participants · Participants
Pembrolizumab ADA Prevalence
ParticipantsCanakinumab + PembrolizumabPembrolizumab Monotherapy
Pembrolizumab ADA Prevalence43
SecondaryPembrolizumab ADA Incidence

Pembrolizumab ADA incidence on treatment was calculated as the percentage of participants who were pembrolizumab treatment-induced ADA positive (post-baseline ADA positive with ADA-negative sample at baseline) and pembrolizumab treatment-boosted ADA positive (post-baseline ADA positive with titer that is at least the fold titer change greater than the ADA-positive baseline titer)

Time frame:
From baseline (Predose on Day 1 of Cycle 1) up to 26 days after last dose of study treatment (assessed up to 10.7 weeks). Cycle = 21 days
Reported as:
Count of participants · Participants
Pembrolizumab ADA Incidence
ParticipantsCanakinumab + PembrolizumabPembrolizumab Monotherapy
Pembrolizumab ADA Incidence34
SecondaryOverall Response Rate (ORR) Based on Local Investigator Assessment Using RECIST v1.1

ORR is defined as the percentage of subjects with confirmed best overall response of complete response (CR) or partial response (PR), as per local investigator's assessment by RECIST 1.1. CR: Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters

Time frame:
From date of randomization to date of surgery, assessed up to 6 weeks
Reported as:
Number · Percentage of participants
Overall Response Rate (ORR) Based on Local Investigator Assessment Using RECIST v1.1
Percentage of participantsCanakinumab MonotherapyCanakinumab + PembrolizumabPembrolizumab Monotherapy
Overall Response Rate (ORR) Based on Local Investigator Assessment Using RECIST v1.10 (0.00 to 10.00)8.6 (1.80 to 23.06)11.1 (1.38 to 34.71)
SecondarySerum Canakinumab Concentration

Canakinumab serum concentrations were determined at the specified time points.

Time frame:
Predose (0 hour) on Day 1 of Cycles 1 and 2 (Cycle =21 days)
Reported as:
Geometric mean · microgram/miliLiter (ug/mL)
Serum Canakinumab Concentration
microgram/miliLiter (ug/mL)Canakinumab MonotherapyCanakinumab + Pembrolizumab
Cycle 10 ± 00 ± 0
Cycle 210.9 ± 32.910.3 ± 41.0
SecondarySerum Pembrolizumab Concentration

Pembrolizumab serum concentrations were determined at the specified time points.

Time frame:
Predose (0 hour) and 0.5 hours post dose on Day 1 of Cycle 1 and predose on Cycle 2 (Cycle =21 days)
Reported as:
Geometric mean · ug/mL
Serum Pembrolizumab Concentration
ug/mLCanakinumab + PembrolizumabPembrolizumab Monotherapy
Cycle 1 predose0 ± 00 ± 0
Cyle 1 0.5 hours post dose65.5 ± 23.865.5 ± 19.9
Cycle 2 predose16.0 ± 43.435.5 ± 13.7
SecondarySurgical Feasibility Rate

Surgical feasibility rate was defined as the percentage of subjects who underwent surgery following study treatment.

Time frame:
Up to 6 weeks after first dose
Reported as:
Number · Percentage of participants
Surgical Feasibility Rate
Percentage of participantsCanakinumab MonotherapyCanakinumab + PembrolizumabPembrolizumab Monotherapy
Surgical Feasibility Rate91.4 (76.94 to 98.20)97.1 (85.08 to 99.93)100 (81.47 to 100.00)
SecondaryMajor Pathological Response (MPR) Rate at the Time of Surgery in Subjects Randomized to Pembrolizumab Monotherapy Based on Central Review

MPR was defined as the percentage of participants with major pathological response (defined as ≤10% residual viable tumor cells on surgical samples). Any participant who had \>10% residual viable cancer cells, or started new antineoplastic therapy prior to surgery, or did not have the surgery performed, or had the surgery performed but with unevaluable MPR result, was considered as a non-responder. MPR was assessed at the time of surgery in all subjects randomized to pembrolizumab monotherapy arm based on central review.

Time frame:
At time of surgery (up to 6 weeks after first dose)
Reported as:
Number · Percentage of participants
Major Pathological Response (MPR) Rate at the Time of Surgery in Subjects Randomized to Pembrolizumab Monotherapy Based on Central Review
Percentage of participantsPembrolizumab Monotherapy
Major Pathological Response (MPR) Rate at the Time of Surgery in Subjects Randomized to Pembrolizumab Monotherapy Based on Central Review16.7 (3.58 to 41.42)
SecondaryDifference in Major Pathological Response (MPR) Rate Between the Canakinumab Plus Pembrolizumab Arm and the Pembrolizumab Arm Based on Central Review

MPR was defined as the percentage of participants with ≤10% residual viable tumor cells on surgical samples. MPR was assessed at the time of surgery based on central review. The difference in MPR rate between the canakinumab plus pembrolizumab arm and the pembrolizumab arm based on central review along with the Chang and Zhang confidence interval was assessed.

Time frame:
At time of surgery (up to 6 weeks after first dose of study treatment)
Reported as:
Number · Percentage of participants
Difference in Major Pathological Response (MPR) Rate Between the Canakinumab Plus Pembrolizumab Arm and the Pembrolizumab Arm Based on Central Review
Percentage of participantsCanakinumab + PembrolizumabPembrolizumab Monotherapy
Difference in Major Pathological Response (MPR) Rate Between the Canakinumab Plus Pembrolizumab Arm and the Pembrolizumab Arm Based on Central Review17.1 (6.56 to 33.65)16.7 (3.58 to 41.42)
Statistical analysis
  • Canakinumab + Pembrolizumab vs Pembrolizumab Monotherapy · Mean difference (final values): 0.5 · 95% CI -25.56 to 21.23
SecondaryMajor Pathological Response (MPR) Rate at the Time of Surgery in All Subjects Based on Local Review

MPR was defined as the percentage of participants with major pathological response (defined as ≤10% residual viable tumor cells on surgical samples). Any participant who had \>10% residual viable cancer cells, or started new antineoplastic therapy prior to surgery, or did not have the surgery performed, or had the surgery performed but with unevaluable MPR result, was considered as a non-responder. MPR was assessed at the time of surgery in all subjects based on local review.

Time frame:
At time of surgery (up to 6 weeks after first dose)
Reported as:
Number · Percentage of participants
Major Pathological Response (MPR) Rate at the Time of Surgery in All Subjects Based on Local Review
Percentage of participantsCanakinumab MonotherapyCanakinumab + PembrolizumabPembrolizumab Monotherapy
Major Pathological Response (MPR) Rate at the Time of Surgery in All Subjects Based on Local Review0 (0.00 to 10.00)20.0 (8.44 to 36.94)22.2 (6.41 to 47.64)
SecondaryMajor Pathological Response (MPR) Rate Based on the Levels of Biomarkers

MPR was defined as the percentage of participants with major pathological response (defined as ≤10% residual viable tumor cells on surgical samples). Any participant who had \>10% residual viable cancer cells, or started new antineoplastic therapy prior to surgery, or did not have the surgery performed, or had the surgery performed but with unevaluable MPR result, was considered as a non-responder. MPR rate was analyzed by the biomarker subgroups at baseline. Biomarkers included PD-L1, CD8, hs-CRP and hs-IL-6.

Time frame:
From date of randomization up to 6 weeks after first dose
Reported as:
Number · Percentage of participants
Major Pathological Response (MPR) Rate Based on the Levels of Biomarkers
Percentage of participantsCanakinumab MonotherapyCanakinumab + PembrolizumabPembrolizumab Monotherapy
PD-L1: <1%0 (0.00 to 26.46)7.1 (0.18 to 33.87)14.3 (0.36 to 57.87)
PD-L1: 1-49%6.7 (0.17 to 31.95)15.4 (1.92 to 45.45)16.7 (0.42 to 64.12)
PD-L1: >=50%0 (0.00 to 45.93)42.9 (9.90 to 81.59)0 (0.00 to 70.76)
hs-CRP: <2mg/L12.5 (0.32 to 52.65)7.7 (0.19 to 36.03)37.5 (8.52 to 75.51)
hs-CRP: >=2mg/L0 (0.0 to 13.23)22.7 (7.82 to 45.37)0 (0.00 to 33.63)
hs-IL-6: <Q1 (2.52 mg/L)16.7 (0.42 to 64.12)12.5 (0.32 to 52.65)14.3 (0.36 to 57.87)
hs-IL-6: >=Q1 (2.52 pg/mL) to <Q2 (5.36 pg/mL)0 (0.00 to 36.94)10 (0.25 to 44.50)33.3 (0.84 to 90.57)
hs-IL-6: >=Q2 (5.36 pg/mL) to <Q3 (12.03 pg/mL)0 (0.00 to 36.94)28.6 (3.67 to 70.96)16.7 (0.42 to 64.12)
hs-IL-6: >=Q3 (12.03 pg/mL)0 (0.00 to 30.85)20.0 (2.52 to 55.61)0 (0.00 to 97.50)
CD8: <3%0 (0.00 to 26.46)13.0 (2.78 to 33.59)0 (0.00 to 52.18)
CD8: >=3%0 (0.00 to 18.53)22.2 (2.81 to 60.01)33.3 (4.33 to 77.72)

Adverse events

Collected over From day of first dose of study medication to 130 days after last dose of study medication, up to 25.6 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Canakinumab Monotherapy3/35 (8.6%)10/35 (28.6%)28/35 (80%)
Canakinumab + Pembrolizumab2/35 (5.7%)9/35 (25.7%)27/35 (77.1%)
Pembrolizumab Monotherapy1/18 (5.6%)4/18 (22.2%)14/18 (77.8%)
Most frequent serious events
Showing 10 of 30
Most frequent serious events
EventCanakinumab MonotherapyCanakinumab + PembrolizumabPembrolizumab Monotherapy
PneumoniaInfections and infestations3/351/350/18
COVID-19Infections and infestations2/351/351/18
HypothyroidismEndocrine disorders0/350/351/18
Upper gastrointestinal haemorrhageGastrointestinal disorders0/350/351/18
HaemothoraxRespiratory, thoracic and mediastinal disorders0/350/351/18
RashSkin and subcutaneous tissue disorders0/350/351/18
ArrhythmiaCardiac disorders1/350/350/18
Cardiac failureCardiac disorders1/350/350/18
Myocardial ischaemiaCardiac disorders1/350/350/18
Immune-mediated hepatitisHepatobiliary disorders0/351/350/18
Most frequent other events
Showing 10 of 69
Most frequent other events
EventCanakinumab MonotherapyCanakinumab + PembrolizumabPembrolizumab Monotherapy
AnaemiaBlood and lymphatic system disorders9/351/351/18
FatigueGeneral disorders9/355/354/18
DiarrhoeaGastrointestinal disorders1/356/350/18
Procedural painInjury, poisoning and procedural complications0/356/352/18
Decreased appetiteMetabolism and nutrition disorders6/351/350/18
CoughRespiratory, thoracic and mediastinal disorders4/356/352/18
DyspnoeaRespiratory, thoracic and mediastinal disorders4/356/351/18
NauseaGastrointestinal disorders4/353/353/18
SARS-CoV-2 test negativeInvestigations2/353/353/18
HyperthyroidismEndocrine disorders0/355/351/18

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Canakinumab MonotherapyCanakinumab + PembrolizumabPembrolizumab MonotherapyTotal
Mean65.5 ± 9.8867.1 ± 6.9866.1 ± 5.6166.2 ± 7.99
Sex: Female, Male
Sex: Female, Male(Participants)Canakinumab MonotherapyCanakinumab + PembrolizumabPembrolizumab MonotherapyTotal
Female1314936
Male2221952
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Canakinumab MonotherapyCanakinumab + PembrolizumabPembrolizumab MonotherapyTotal
White20251257
Asian73212
Black or African American1102
American Indian or Alaska Native0101
Unknown75416
08

Study locations

29 sites
  • UCLA Oncology Hematology
    La Jolla, California 92037, United States
  • University of Kansas Medical Center Neurology Dept.
    Kansas City, Kansas 66160, United States
  • SUNY - Upstate Medical University
    Syracuse, New York 13210, United States
  • Methodist Hospital / Methodist Cancer Center
    Houston, Texas 77030, United States
  • Novartis Investigative Site
    Bruxelles, 1000, Belgium
  • Novartis Investigative Site
    Montreal, Quebec H2W 1T8, Canada
  • Novartis Investigative Site
    Montpellier cedex 5, Herault 34059, France
  • Novartis Investigative Site
    Bron, 69677, France
  • Novartis Investigative Site
    Paris, 75679, France
  • Novartis Investigative Site
    Bad Berka, 99437, Germany
  • Novartis Investigative Site
    Giessen, 35392, Germany
  • Novartis Investigative Site
    Halle (Saale), 06120, Germany
  • Novartis Investigative Site
    Koeln, 51109, Germany
  • Novartis Investigative Site
    Thessaloniki, 57001, Greece
  • Novartis Investigative Site
    Kashiwa, Chiba 277 8577, Japan
  • Novartis Investigative Site
    Breda, 4819 EV, Netherlands
  • Novartis Investigative Site
    Hertogenbosch, 5200, Netherlands
  • Novartis Investigative Site
    Maastricht, 6229 HX, Netherlands
  • Novartis Investigative Site
    Omsk, 644013, Russian Federation
  • Novartis Investigative Site
    Saint Petersburg, 197022, Russian Federation
  • Novartis Investigative Site
    St Petersburg, 195271, Russian Federation
  • Novartis Investigative Site
    Jaen, Andalucia 23007, Spain
  • Novartis Investigative Site
    Oviedo, Asturias 33011, Spain
  • Novartis Investigative Site
    Madrid, 28034, Spain
  • Novartis Investigative Site
    Taipei, 103616, Taiwan
  • Novartis Investigative Site
    Taipei, 110, Taiwan
  • Novartis Investigative Site
    Izmir, Turkey
  • Novartis Investigative Site
    Sakarya, 54290, Turkey
  • Novartis Investigative Site
    Sihhiye / Ankara, 06100, Turkey
09

References and documents

Publications

  • Garrido P, Pujol JL, Kim ES, Lee JM, Tsuboi M, Gomez-Rueda A, Benito A, Moreno N, Gorospe L, Dong T, Blin C, Rodrik-Outmezguine V, Passos VQ, Mok TS. Canakinumab with and without pembrolizumab in patients with resectable non-small-cell lung cancer: CANOPY-N study design. Future Oncol. 2021 Apr;17(12):1459-1472. doi: 10.2217/fon-2020-1098. Epub 2021 Mar 2. PubMed 33648347 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data is currently available according to the process described on www.clinicalstudydatarequest.com.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2019 to primary completion in Apr 2022, 29 months.

Results were first posted in Jul 2023, 1 year 2 months after primary completion. A results delay was requested in Jul 2022.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2019
First posted
May 30, 2019
StartActual
Nov 5, 2019
Primary completionActual
Apr 20, 2022
CompletionActual
Aug 15, 2022
Results delay requested
Jul 5, 2022
Results first posted
Jul 3, 2023
Last update
Jun 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03968419
Responsible party
Sponsor
First posted
May 30, 2019
Start date
Nov 5, 2019
Primary completion
Apr 20, 2022
Completion
Aug 15, 2022
Results posted
Jul 3, 2023
Last update
Jun 20, 2024

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Canakinumab · Pembrolizumab

Start the discussion